QLGN - Qualigen begins IND-enabling studies to advance potential cancer treatment toward clinical trials

Qualigen Therapeutics (NASDAQ:QLGN -1.6%) said on Tuesday it had begun IND-enabling studies for its lead program, QN-302, to treat pancreatic cancer, and potentially prostate cancer and other solid tumors. The company said its Investigational New Drug, or IND-enabling studies, combined with the data package in-licensed from University College London (UCL), align with the timeline for the submission of an application to begin trial to the U.S. FDA during the first half of 2023. It expects to initiate exploratory toxicology study during the third quarter.

For further details see:

Qualigen begins IND-enabling studies to advance potential cancer treatment toward clinical trials